VOR:NASDAQVor Biopharma Inc. Analysis

Vor Biopharma (VOR) is trading at $16.94, which sits just below its 20‑day SMA of $15.17 and comfortably above the 50‑day SMA of $14.96, while remaining well under the 200‑day SMA of $21.75, indicating a short‑term price lift but a longer‑term downtrend. The MACD line sits at 0.205 with a bullish signal, and the RSI of 61.6 suggests momentum is still healthy but not overbought. Volatility is extreme at 91% over the past 30 days and a beta of ~2.0 points to amplified market moves, compounded by a historic max drawdown of –87%, underscoring a high‑risk profile. Extreme Greed sentiment (FGI 90.73) and a calculated upside/downside potential of 121% further highlight speculative interest despite the bearish long‑term trend.
Fundamentally, VOR reports zero revenue, negative EBITDA of $‑339 M, and ongoing cash burn (operating cash flow $‑143 M, free cash flow $‑181 M), yet holds $455 M in cash and minimal debt. The stock has a strong‑buy consensus from eight analysts with a median price target of $40, implying a potential upside of over 130% from current levels. Recent material news includes multiple inducement grants to new employees, signaling continued talent acquisition, while notable share sales by RA Capital hint at short‑term selling pressure. Given the lack of dividends, negative earnings multiples, and high clinical‑stage risk, the valuation appears undervalued relative to analyst targets, but the company remains a high‑risk, growth‑oriented play.